Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the financial performance of Tarsus’ only marketed product in the United States, Xdemvy, approved for demodex blepharitis. The company i ...